🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

393,17 USD

Máx. histórico

447,03

14 días

Split 2:1 del 22/11/1999

Caída desde máximo

-12,05%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-10,08%

Cierre anterior

437,23

Rango de hoy

391,17 – 410,03

Volumen hoy

6.589.429

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
24,44 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 5 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,53%
Fecha de pago Importe por participación
16/11/2022 1,9400 USD
17/08/2022 1,9400 USD
16/05/2022 1,9400 USD
14/02/2022 1,9400 USD
15/11/2021 1,7600 USD
16/08/2021 1,7600 USD
14/05/2021 1,7600 USD
11/02/2021 1,7600 USD
13/11/2020 1,6000 USD
14/08/2020 1,6000 USD
15/05/2020 1,6000 USD
13/02/2020 1,6000 USD
14/11/2019 1,4500 USD
14/08/2019 1,4500 USD
16/05/2019 1,4500 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/04/2003 63,50 64,45 62,93 63,99 +0,30% 2,39% 12.749.300
23/04/2003 62,21 63,83 62,00 63,80 +4,69% 2,94% 24.200.600
22/04/2003 59,80 61,00 59,80 60,94 +1,43% 2,01% 13.535.400
21/04/2003 60,31 60,90 59,80 60,08 -0,08% 1,82% 8.732.200
17/04/2003 59,70 60,25 59,30 60,13 +0,99% 1,59% 9.571.900
16/04/2003 60,30 60,37 58,94 59,54 -1,01% 2,37% 10.427.600
15/04/2003 59,26 60,17 59,24 60,15 +1,81% 1,57% 11.199.600
14/04/2003 58,07 59,38 57,91 59,08 +2,07% 2,53% 7.846.100
11/04/2003 58,24 58,68 57,30 57,88 -0,12% 2,37% 7.110.500
10/04/2003 57,53 58,11 56,90 57,95 +0,61% 2,10% 8.214.800
09/04/2003 58,58 59,00 57,60 57,60 -1,79% 2,39% 9.252.900
08/04/2003 58,20 59,09 58,10 58,65 +0,41% 1,70% 10.071.200
07/04/2003 59,90 60,25 58,11 58,41 -1,47% 3,57% 12.137.000
04/04/2003 59,66 59,96 59,07 59,28 -0,20% 1,49% 7.379.600
03/04/2003 59,73 59,95 58,95 59,40 -0,55% 1,67% 11.268.800
02/04/2003 59,48 59,80 59,15 59,73 +2,07% 1,09% 10.091.500
01/04/2003 57,92 58,90 57,80 58,52 +1,69% 1,90% 9.856.000
31/03/2003 58,14 58,44 57,55 57,55 -1,72% 1,53% 10.223.500
28/03/2003 58,40 58,96 58,35 58,56 -0,02% 1,04% 7.319.700
27/03/2003 57,75 58,70 57,60 58,57 +1,07% 1,90% 9.756.300
26/03/2003 58,36 59,06 57,89 57,95 -0,87% 2,00% 10.127.100
25/03/2003 57,55 58,94 57,53 58,46 +1,95% 2,45% 9.857.100
24/03/2003 57,79 58,16 57,13 57,34 -2,08% 1,78% 11.078.700
21/03/2003 58,75 58,98 57,84 58,56 +1,02% 1,94% 11.324.400
20/03/2003 58,14 58,25 57,11 57,97 -0,57% 1,96% 11.190.700
19/03/2003 58,75 59,00 57,75 58,30 -0,97% 2,13% 11.871.200
18/03/2003 58,60 58,92 58,07 58,87 +0,44% 1,45% 10.824.900
17/03/2003 57,31 58,90 57,12 58,61 +1,68% 3,11% 13.643.200
14/03/2003 56,94 58,02 56,65 57,64 +1,12% 2,41% 14.468.700
13/03/2003 55,81 57,00 55,40 57,00 +3,34% 2,87% 14.876.200